Abstract
Cyclophosphamide (CP) is an antineoplastic agent used alone or in combination with other chemotherapeutic agents for the treatment of many neoplastic diseases. Hemorrhagic cystitis (HC) is a major potential toxicity and dose limiting side effect of CP. Recently, it has been shown that endogenous inflammatory mediators are involved in cystitis by increasing nitric oxide (NO) production in target tissue. The aim of this study was to evaluate the relationship between NO and CP induced hemorrhagic cystitis HC in rats. A total of 30 female Spraque-Dawley rats were divided into 4 groups. Group 1 served as control, three groups received single dose of CP (100 mg/kg) intraperitoneally (i.p.): group 2 received CP only. Group 3 received the NO precursor L-arginine (80 mg/kg/day), and group 4 received the selective inducible NO synthase (iNOS) inhibitor S-methylisothiourea (SMT; 20 mg/kg/day) before and the day after cyclophosphamide injection. CP injection resulted in severe cystitis. SMT but not L-arginine produced marked inhibition of CP induced bladder damage. We concluded that NO produced by iNOS, is an important mediator in the pathogenesis of CP induced cystitis.
Similar content being viewed by others
References
Levine LA, Richie JP (1989) Urological complications of cyclophosphamide. J Urol 141:1063–1069
Philips FS, Sternberg SS, Cronin AP, Vidal PM (1961) Cyclophosphamide and urinary bladder toxicity. Cancer Res 21:1577–1589
Brock N, Pohl J, Stekar J (1981) Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. I.Experimental studies on the urotoxicity of alkylating compounds. Eur J Cancer 17:595–607
West NJ (1997) Prevention and treatment of hemorrhagic cystitis. Pharmacotherapy 17:696–706
Brock N, Pohl J (1983) The development of mesna for regional detoxification. Cancer Treat Rev 10[suppl A]:33–43
Gomes TN, Santos CC, Souza-Filho MV, Cunha FQ, Ribeiro RA (1995) Participation of TNF-α and IL-1 in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis. Braz J Med Biol Res 28:1103–1108
Souza-Filho MV, Lima MV, Pompeu MM, Ballejo G, Cunha FQ, Ribeiro RA (1997) Involvement of nitric oxide in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis. Am J Pathol 150:247–256
Ribeiro RA, Feritas HC, Campos MC, Santos CC, Figueiredo FC, Brito GA, Cunha FQ (2002) Tumor necrosis factor-α and interleukin-1β mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice. J Urol 67:2229–2234
Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharm Rev 43:109–142
Hibbs JB, Taintor RR, Vavrin Z (1987) Macrophage cytotoxicity: role forL-arginine deiminase and imino nitrogen oxidation to nitrite. Science 235:473–476
Tracey WR, Tse J, Carter G (1995) Lipopolisaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors. J Pharmacol Exp Ther 272:1011–1015
Xu X, Cubeddu LX, Malave A (2001) Expression of inducible nitric oxide synthase in primary culture of rat bladder smooth muscle cells by plasma from cyclophosphamide-treated rats. Eur J Pharmacol 416:1–9
Alfieri AB, Cubeddu LX (2000) Nitric oxide and NK1-tachykinin receptors in cyclophosphamide-induced cystitis, in rats. J Pharmacol Exp Ther 295: 824–829
Alfieri AB, Malave A, Cubeddu LX (2001) Nitric oxide synthases an cyclophosphamide-induced cystitis in rats. Naunyn Schmiedebergs Arch Pharmacol 363:353–357
Moncada S, Higgs A, Furchgott R (1997) International union of pharmacology nomenclature in nitric oxide research. Pharm Rev 49:137–142
Acknowledgements
This work was supported by the Gulhane Military Medical Academy Research and Progress Center (AR-2001/48).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oter, S., Korkmaz, A., Oztas, E. et al. Inducible nitric oxide synthase inhibition in cyclophosphamide induced hemorrhagic cystitis in rats. Urol Res 32, 185–189 (2004). https://doi.org/10.1007/s00240-003-0398-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00240-003-0398-y